Carl June: A "living drug" that could change the way we treat cancer
Carl June is a renowned pioneer in the fight against cancer. Full bio
Double-click the English transcript below to play the video.
I've told this story in public,
baseball player who said,
in the road, take it."
for more than a century,
as a way to fight cancer,
unfortunately, been disappointing.
caused by viruses,
gave up on the idea
to fight cancer.
did not evolve to fight cancer;
invading from the outside.
bacteria and viruses.
has trouble with most cancers
from the outside;
not recognize the cancer as a problem,
and also our normal cells,
like colitis or multiple sclerosis.
synthetic immune systems
and kill cancer cells.
a synthetic immune system.
and synthetic biology.
parts of the immune system,
cells infected with viruses,
antibodies that are secreted
these two functions
to repurpose them to fight cancer?
to insert the genes for antibodies
as a Trojan horse
from Greek mythology,
and a serpent's tail.
thing that we had created
our T cells carrier
Receptor T cells," or CAR T cells.
into their killing mode.
into somebody with cancer,
see and bind to their tumor target?
T cells on steroids.
buildup system in the body
and multiply by the millions,
are the first living drug in medicine.
and then you have to take them again --
and on the job for years.
in the bodies of our cancer patients
cancer T cells, CAR T cells,
of more than 17 years.
for the rest of your life.
of a new paradigm in medicine.
to these T-cell infusions.
that will work in a patient
an identical twin.
the patient's own T cells.
platform for this in the 1990s.
CAR T cells in patients
survived in the patients
and decreased their viruses,
and over the next decade
to the CAR T cell design.
leukemia patients.
lymphocytic leukemia in 2012.
every year in the United States.
was a retired Marine sergeant
for his funeral.
and within days, he had high fevers.
and was comatose.
fork in the road happened.
the CAR T cell infusion,
had been there had melted.
no evidence of leukemia,
three patients we treated,
now for eight years,
the leukemia in these patients
and 7.7 pounds of tumor in each patient.
bioreactors for these CAR T cells,
and millions of CAR T cells
blood and tumor masses.
can punch far above their weight class,
1,000 tumor cells.
of one to a thousand.
its daughter progeny cells
and divide in the body
in cancer medicine.
who had full remission
who had run out of options,
for those forks in the road.
to treat children with acute leukemia,
on the trial was Emily Whitehead,
a series of chemotherapy
over several years,
was advanced, incurable leukemia.
her liver, her spleen.
with the CAR T cells
she did not get better.
officer had in 2010,
in the whole road of this story.
and on life support
as 106 degrees Fahrenheit for three days.
what was causing those fevers.
blood tests for infections,
an infectious cause for her fever.
very unusual in her blood
before in medicine.
called interleukin-6, or IL-6,
above the normal levels.
fork in the road came in.
of pediatric arthritis.
following as a cancer doc,
for arthritis for my daughter,
before Emily was admitted to the hospital,
that my daughter had.
to the pharmacy at Emily's hospital,
these very high levels of IL-6,
with this arthritis drug?"
for suggesting that.
to the institutional review board,
short of striking.
with tocilizumab,
and still in remission.
of the high fevers and coma,
all patients who respond to the therapy.
in those patients who fail to respond.
for these high fevers after therapy,
"the worst flu in their life,"
of the twisting and turning path
are often those who are not cured.
to eradicate leukemia.
CAR T cells for leukemia,
of tocilizumab to block the IL-6 effects
in these patients.
in medical history.
completed further trials
the first 30 we treated,
in patients with advanced cancer
success in a cancer trial
had a complete response rate.
"New England Journal of Medicine" in 2013.
has since confirmed those results.
leukemia in August of 2017.
of a cell and gene therapy,
has also been tested now
a year in the United States.
and have been durable to date.
the therapy of this advanced lymphoma
and scientists around the world
with the rapid pace of advancement.
who were formerly terminal
that may, in fact, be a cure.
about the financial cost.
to make the CAR T cells for each patient.
of treating CRS and other complications,
one million dollars per patient.
of failure, though, is even worse.
for cancer are also expensive
research done now
to all patients.
and evolving field,
therapies and services,
to do things more efficiently.
all the forks in the road
as very important.
of this magnitude don't happen overnight.
after a 30-year journey,
and surprises.
vision and patience
is not always a dilemma or a detour;
we may not know it at the time,
ABOUT THE SPEAKER
Carl June - Oncologist, researcher, professorCarl June is a renowned pioneer in the fight against cancer.
Why you should listen
Carl June's revolutionary leukemia therapy, which was recently approved by the FDA, uses genetically engineered versions of a patient’s own T cells and is the first personalized cell therapy for cancer to be sanctioned in America. Developed by June and his colleagues, this method has the potential to help patients with many other types of cancers.
June is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. A graduate of the Naval Academy in Annapolis and Baylor College of Medicine, he has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, as well as being named one of TIME Magazine's 100 Most Influential People in 2018.
Carl June | Speaker | TED.com